Pfizer has announced the planned leadership and organisational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes.

 

The company will establish a unique research model designed to advance the scientific capabilities of both Pfizer and Wyeth and to support the new company's nine diverse health care businesses. At the senior-most level of the organisation, Pfizer will retain eight senior executives from Wyeth who will join the company post-closing.

 

CEOs Jeff Kindler and Bernard Poussot and senior leadership of both companies continue to work closely together through the integration process. As planning continues, additional appointments are expected that will enable Pfizer to begin appreciating the benefits of the combined company with a new team and structure in place immediately following the close of the acquisition.

 

To maximise new opportunities in biopharmaceutical research, Pfizer will form two distinct research organizations. The PharmaTherapeutics Research Group will focus on the discovery of small molecules and related modalities and will be led by Martin Mackay, who now leads Pfizer Global Research & Development (PGRD). The BioTherapeutics Research Group will focus on large-molecule research, including vaccines, and will be led by Mikael Dolsten, who currently serves as President of Wyeth Research. Both Dr. Dolsten and Dr. Mackay will serve as presidents of their respective organisations and members of Pfizer's Executive Leadership Team, and both will report to Pfizer Chairman and Chief Executive Officer Jeff Kindler.

 

Within these two research groups, small, focused scientific teams will be led by Chief Scientific Officers. These teams will be responsible for creating a rich portfolio of both small and large molecules from across both research organisations and, in particular, with delivering positive proofs-of-concept for Pfizer's business units to develop.

 

Emilio Emini, who currently heads Wyeth's Vaccine Research; and Development, will join Pfizer as Chief Scientific Officer, Vaccine Research, and Menelas Pangalos, who currently serves as Wyeth's Head of Discovery, will join Pfizer as Chief Scientific Officer, Neuroscience Research.

 

The new Pfizer will consist of nine diverse global health care businesses, and will be led by executives from both Pfizer and Wyeth.

 

Ian Read, currently President of Worldwide Pharmaceutical Operations for Pfizer, will become Group President, Pfizer BioPharmaceutical Businesses, and remain a member of the Executive Leadership Team reporting to Mr. Kindler.

 

Primary Care will be led by President Olivier Brandicourt, while Specialty Care and Vaccines will be led by President Geno Germano, currently President of Wyeth's U.S. and Pharmaceuticals business units.

 

Jim Connolly, currently Wyeth's Executive Vice President & General Manager, Vaccines, will join the Specialty Care and Vaccines Business Unit as President, Vaccines, reporting to Germano.

 

Emerging Markets will continue to be led by President Jean-Michel Halfon and will have a significantly enhanced presence in high-growth, less-developed and under-penetrated markets, including those in Latin America, the Middle East and China.

 

Oncology will continue to be led by President Garry Nicholson, while Established Products will also continue to be led by President David Simmons.

 

Cavan Redmond, currently President of Wyeth's Consumer Healthcare business, will become Group President, Pfizer Diversified Businesses, join Pfizer's Executive Leadership Team and report to Mr. Kindler.

 

Animal Health will continue to be led by President Juan-Ramón Alaix and will have an enhanced leading position in the industry, with important large animal and companion animal products and a platform that includes vaccines, parasiticides and anti-infectives.

 

Capsugel will continue to be led by President Guido Driesen and Consumer Health will be led by President Paul Sturman, currently President, US and Global Business Development, New Products for Wyeth Consumer Healthcare.

 

Nutritional Health will be led by President Erica Mann, currently Managing Director of Wyeth Australia and New Zealand.

 

The leadership team will begin working together immediately upon the completion of the Wyeth acquisition. Until the acquisition is complete, Pfizer and Wyeth leadership will continue in their current roles. Pfizer and Wyeth continue to expect the transaction to close at the end of the third quarter or during the fourth quarter of 2009.